(Q52935004)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26112218%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

title

Pyruvate kinase isoenzyme M2 is a therapeutic target of gemcitabine-resistant pancreatic cancer cells (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26112218%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

1 reference

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26112218%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Kyoungbun Lee

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26112218%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

13

Young Il Yeom

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26112218%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

author name string

Dong Joon Kim

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26112218%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Young Soo Park

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26112218%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Min Gu Kang

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26112218%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Yeon-Mi You

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26112218%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Yuri Jung

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26112218%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Han Koo

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26112218%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Jung-Ae Kim

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26112218%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Mi-Ju Kim

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26112218%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Ja-June Jang

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26112218%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Kyung Chan Park

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26112218%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

language of work or name

English

0 references

publication date

22 June 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26112218%20AND%20SRC:MED&resulttype=core&format=json

Experimental Cell Research

18 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26112218%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

volume

336

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26112218%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26112218%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

page(s)

119-129

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26112218%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.05.017

Recurrence after resection for ductal adenocarcinoma of the pancreas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.05.017

Gemcitabine: progress in the treatment of pancreatic cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.05.017

Cytotoxic chemotherapy for pancreatic cancer: Advances to date and future directions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.05.017

7 January 2021

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.05.017

The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.05.017

CNT1 expression influences proliferation and chemosensitivity in drug-resistant pancreatic cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.05.017

Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.05.017

RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.05.017

Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.05.017

Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.05.017

Gemcitabine-based chemogene therapy for pancreatic cancer using Ad-dCK::UMK GDEPT and TS/RR siRNA strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.05.017

Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.05.017

Hallmarks of Cancer: The Next Generation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.05.017

Why do cancers have high aerobic glycolysis?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.05.017

The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.05.017

Pyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.05.017

HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.05.017

ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.05.017

Pyruvate kinase M2 regulates gene transcription by acting as a protein kinase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.05.017

Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.05.017

Acetylation targets the M2 isoform of pyruvate kinase for degradation through chaperone-mediated autophagy and promotes tumor growth.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.05.017

Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.05.017

JMJD5 regulates PKM2 nuclear translocation and reprograms HIF-1α-mediated glucose metabolism.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.05.017

PKM2: a gatekeeper between growth and survival.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.05.017

PKM2 phosphorylates histone H3 and promotes gene transcription and tumorigenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.05.017

Lysyl oxidase like 4, a novel target gene of TGF-beta1 signaling, can negatively regulate TGF-beta1-induced cell motility in PLC/PRF/5 hepatoma cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.05.017

A novel pyruvate kinase M2 activator compound that suppresses lung cancer cell viability under hypoxia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.05.017

Gemcitabine-mediated tumour regression and p53-dependent gene expression: implications for colon and pancreatic cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.05.017

Phosphorylation of human p53 by p38 kinase coordinates N-terminal phosphorylation and apoptosis in response to UV radiation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.05.017

Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.05.017

DYRK2 is targeted to the nucleus and controls p53 via Ser46 phosphorylation in the apoptotic response to DNA damage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.05.017

Protein kinase C delta regulates Ser46 phosphorylation of p53 tumor suppressor in the apoptotic response to DNA damage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.05.017

Rocking cell metabolism: revised functions of the key glycolytic regulator PKM2 in cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.05.017

Overcoming nucleoside analog chemoresistance of pancreatic cancer: a therapeutic challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.05.017

The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.05.017

10.1016/J.YEXCR.2015.05.017

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26112218%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

1 reference